Education and Science, Estonia, Good for Business, Investments, Markets and Companies, Medicine
International Internet Magazine. Baltic States news & analytics
Wednesday, 24.04.2024, 23:29
Indian pharmaceutical Bravo Grupp's plant in Estonia to cost EUR 3.2 mln
"For now the plan is
to hire 32 employees, who should be engineers or chemical engineers by
training," said Riin Ehin, member of the management board of
the Competence Center for Cancer Research (CCCR), which is responsible for
launching the plant in Estonia.
She said that while there
could be minor deviations from the original project cost due to climate, the
estimated construction cost is from 3.2 to 3.6 million euros.
"Renewal of
installations, quality control, training of employees – everything is
standardized. While some minor modifications have to be made and maybe some
materials substituted, work on the design is under way now in principle,"
Ehin said.
She added that there was
an agreement in principle with the builder, but wouldn't disclose the name of
the contractor yet.
The manager said the
company was very satisfied with the location, describing proximity to Tallinn
Airport and the Tallinn University of Technology as very important factors in
choosing the location. She did not rule out the possibility that in the future
a second plant will be built in or near Tartu, where the plant was originally
planned to be located.
Construction of the plant
is planned to start soon and the estimated duration of the works is 18 months.
Bravo Grupp is about to build a 3,000
square meter pharmaceutical plant in the Rae technology park at Juri, a small
town situated to the south of Tallinn, to make generic drugs primarily for the
Asian and African markets. The final selection of the products will be made in
collaboration with the Ministry of Social Affairs and the Estonian Health
Insurance Fund.
Bravo Grupp at present has two plants
in India, one in Uzbekistan and one in Uganda.
Bravo Grupp has acquired a holding
in the Competence Center for Cancer Research (CCCR). According to the
Business Register, the shareholders of CCCR are Ibcc Holding AS, AS Cambrex
Tallinn, North Estonia Medical Center, Tfs Trial Form, Cemines Estonia OU
and AS Kevelt.